VIMTALABS Vimta Labs Q2 FY26 results (Jul–Sep 2025) and concall
Vimta Labs reported a strong Q2 FY26, achieving its highest ever quarterly revenue of INR1,045 million, a 22.3% YoY increase. This growth was primarily driven by pharmaceutical and food testing services, with robust EBITDA margins of 35.3%. The company remains net debt-free and is on track with its capacity expansion plans, including the biologics project slated for commercialization by Q1 FY27.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 20.0%, net profit up 33.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 85 | 90 | 94 | 98 | 102 +20% |
| EBITDA | 30 | 33 | 33 | 34 | 34 +13% |
| Net profit | 15 | 22 | 18 | 19 | 20 +33% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
